MedWellAI (MWAI) EBITDA (2012 - 2026)

MedWellAI has disclosed EBITDA across 14 years of filings, most recently posting -$219367.0 for Q1 2026.

• In Q1 2026, EBITDA rose 72.74% year-over-year to -$219367.0; the TTM figure through Mar 2026 stood at -$1.9 million (up 50.45% YoY), while the FY2025 annual figure was -$2.8 million, up 69.04% from the prior year.
• EBITDA improved to -$219367.0 in Q1 2026, from -$265417.0 in the prior quarter.
• Over the last five years, EBITDA for MWAI reached as high as $1.0 million in Q1 2024 and fell as low as -$22.1 million in Q2 2023.
• The 5-year median for EBITDA is -$559465.0 (2022), against an average of -$2.2 million.
• Annual changes were most pronounced in 2023 — EBITDA sank 3853.89% — and 2024, when it jumped 505.02%.
• A 5-year view of EBITDA shows it stood at -$610649.0 in 2022, then surged by 45.03% to -$335679.0 in 2023, then grew by 9.24% to -$304648.0 in 2024, then advanced by 12.88% to -$265417.0 in 2025, then grew by 17.35% to -$219367.0 in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$219367.0, -$265417.0, and -$317727.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.